Lack of Prenylated Proteins, Autophagy Impairment and Apoptosis in SH-SY5Y Neuronal Cell Model of Mevalonate Kinase Deficiency by Tricarico, Paola Maura et al.
Cell Physiol Biochem 2017;41:1649-1660
DOI: 10.1159/000471235
Published online: March 28, 2017 1649
Tricarico et al.: Prenylated Proteins and Autophagy in MKD
Cellular Physiology 
and Biochemistry
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb
Original Paper
Accepted: March 10, 2017 
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution 
for commercial purposes as well as any distribution of modified material requires written permission.
I: 0.1159/0 471235
lished online: March 28, 2017
© 2017 The Author(s) 
Published by S. Karger AG, Basel
www.karger.com/cpb
© 2017 The Author(s)
Published by S. Karger AG, Basel
Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Via dell’Istria, 65/1 – 
34137 Trieste, (Italy)
Tel. +39 040 3785422, Fax +39 040 3785210, E-Mail fulvio.celsi@gmail.com
Fulvio Celsi, BsC, PhD
Lack of Prenylated Proteins, Autophagy 
Impairment and Apoptosis in SH-SY5Y 
Neuronal Cell Model of Mevalonate Kinase 
Deficiency
Paola Maura Tricaricoa   Alessandra Romeob   Rossella Grattonb   Sergio Crovellaa,b   
Fulvio Celsia
aInstitute for Maternal and Child Health – IRCCS “Burlo Garofolo” – Trieste, bUniversity of Trieste, Trieste, 
Italy
Key Words
Mevalonate Kinase • Mevalonate Kinase Deficiency • Autophagy • Apoptosis • LC-3 • Rho-A • 
Prenylation • GFP   
Abstract
Background/Aims: Mevalonate Kinase Deficiency (MKD), is a hereditary disease due to 
mutations in mevalonate kinase gene (MVK). MKD has heterogeneous clinical phenotypes: the 
correlation between MVK mutations and MKD clinical phenotype is still to be fully elucidated. 
Deficiency of prenylated proteins has been hypothesized as possible MKD pathogenic 
mechanism. Based on this hypothesis and considering that neurologic impairment characterizes 
Mevalonic Aciduria (MA), the most severe form of MKD, we studied the effects of I268T and 
N301T MVK mutations on protein prenylation, autophagy and programmed cell death in SH-
SY5Y neuroblastoma cell lines. Methods: SH-SY5Y cells were transiently transfected, with the 
pCMV-6 plasmid containing MVK wild type and the two mutated sequences. Protein prenylation 
levels were evaluated using GFP-RhoA-F to assess farnesylation, and GFP-RhoA to evaluate 
geranylgeranylation; autophagy was measured by evaluating LC3 and p62 protein levels, while 
Annexin V-FITC and Propidium Iodide staining allowed apoptosis detection. Results: MVK 
mutants’ over-expression causes decreased levels of farnesylation and geranylgeranylation, 
and also increased LC3 lipidation in SH-SY5Y, with concomitant p62 accumulation. Treatment 
with bafilomycin A1 (an inhibitor of vacuolar H+-ATPase, a late autophagy inhibitor) further 
increase LC3-II and p62 levels, suggesting that degradation of autophagolysosome could 
be impaired. SH-SY5Y, with both MVK mutants, showed apoptosis increase; the presence of 
N301T associated with augmented cell death. Conclusions: We hypothesize that mevalonate 
pathway impairment causes alteration of farnesylation and geranylgeranylation proteins and 
alteration of the autophagic flux; these changes can induce apoptosis, possibly more relevant 
in the presence of N301T mutation. 
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Introduction
Mevalonate Kinase Deficiency (MKD) is an auto inflammatory and monogenic disease 
caused by mutations in mevalonate kinase gene (MVK, 12q24.11, NM_000431) that encodes 
for a key enzyme of mevalonate pathway, the Mevalonate Kinase (MK) protein (EC:2.7.1.36) 
(see Fig. 1a for complete description). MKD shows heterogeneous clinical phenotypes, with 
a milder form of the disease known as Hyper-IgD Syndrome (HIDS, OMIM #260920) and a 
more severe one, the Mevalonic Aciduria (MA, OMIM #610377).
MA patients are characterized by recurrent fever attacks (>38.5 °C), with skin rashes, 
hepatosplenomegalia, cutaneous rash, aphtae, arthralgia, abdominal pain with diarrhoea and 
vomiting and by critical neurologic phenotype with psychomotor retardation, hepatopathy 
and cerebellar ataxia [1, 2]. More than 50% of MA patients die in infancy or early childhood 
and few of them survive to adolescence [3]. 
MVK genetic variants are known to be associated with MKD (at present 204 variations 
have been reported according to INFEVERS database, http://fmf.igh.cnrs.fr/ISSAID/
infevers/); however, MKD can shows great genotype–phenotype heterogeneity, as the same 
mutations could be associated both to severe and mild form of the disease, as observed for 
the I268T mutation [4–6]; moreover, there are other mutations specific just for the severe 
form, MA, such as N301T [7–9]. Genotype-phenotype heterogeneity could be related to the 
presence of other modifier genes that predispose or amplify deregulation of the mevalonate 
pathway in this disease [10, 11]. Despite the various studies conducted in this direction, the 
role of these genes has yet not been clarified. Thus, the link between the genetic defects and 
MKD phenotypes remains to be elucidated.
The severity of MKD is correlated with MK enzymatic activity: if it drops below 1% it 
leads to MA, while if its levels are between 1% to 7% it leads to the milder form of MKD [8]; 
unfortunately, the precise correlation between MVK gene mutation and possible alterations 
in MK enzyme structure has not been completely explained. Recently, an article predicted the 
in silico effects of MVK known mutations in the three-dimensional structure of the enzyme, 
identifying two hot spot regions (comprised between residues 8-35 and 234-338) for MA. 
These two regions are located around the inside of protein’s cleft close to the active site 
and around the domain interface [12]. Therefore, variations of these amino acid residues, 
distorting the active site conformation, have been hypothesized as responsible for the low 
MK activity found in MA.
Mevalonate pathway is fundamental for the production of cholesterol and other 
molecules, such as farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate, crucially 
involved in protein prenylation [13]. Protein prenylation is a key biochemical modification 
responsible for targeting specific proteins to cell membranes and activating specific protein 
for normal cell metabolism [13] (see Fig. 1a for complete description of the pathway). 
One of the major accredited MKD pathogenic hypothesis relies on the lack of prenylated 
proteins: the activation of two small GTPase (RhoA and Rac1), which requires geranygeranyl 
pyrophosphate, has been reported as disrupted in fibroblasts from MKD patients [14]. Van der 
Burgh and co-authors subsequently confirmed this pathogenetic hypothesis and expanded 
it, suggesting a strong link between shortage of prenylated proteins, mitochondrial damage 
and autophagy. In previous studies, we also observed a correlation between mevalonate 
pathway impairment, obtained by administration of the pathway blocker Lovastatin, and 
mitochondrial damage that induces an increase of apoptosis, in neuronal, microglial and 
monocytic cell lines [15–17]. 
Considering that the sole available findings on MKD pathogenesis used biochemical 
model [18] and no genetic model mimicking the effects of MVK mutations in vitro has been 
proposed at present time, we established a transient expression model in neuroblastoma 
cell line (SH-SY5Y) using MVK coding plasmid carrying two different mutations: I268T 
(HGMD CM990888) and N301T (HGMD CM920489). A number of different mutations 
have been associated either with HIDS or MA, but we decided to focus our attention on 
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these two mutations since both localized in the in silico predicted hot spot region for MA 
[12]. Furthermore, I268T, when present in homozygosity is associated with MA, while 
in heterozygosity could be linked to HIDS; it is also the second-most frequent mutation 
associated with MKD. N301T instead, is specifically associated to MA, with an undetectable 
level of enzymatic activity. All this considered we evaluated the effects of MVK mutants’ over-
expression in SH-SY5Y neuronal cell line focusing on the important neuronal impairment 
typical of MA patients by analysing protein prenylation levels, autophagic flux and cell death. 
Materials and Methods
Cell Culture
SH-SY5Y neuroblastoma cells were chosen considering that the more severe clinical signs characterizing 
MA (the most severe phenotype of MKD) involve the nervous system; moreover SH-SY5Y cells are a widely 
used model for neurodegenerative disease, possess neuronal features and are easy to transfect. 
SH-SY5Y, kindly provided by Prof. S. Gustincich (Department of Neurobiology, International School 
for Advanced Studied S.I.S.S.A.-I.S.A.S. Trieste, Italy) were cultured in 44.5% MEM/EBSS (Euroclone, Italy), 
44.5% HAM’S/F12 (Euroclone, Italy), supplemented with 10% fetal bovine serum (FBS, Euroclone, Italy), 
non-essential amino acid solution 1× (NEAA, Euroclone, Italy), 2 mM glutamine and penicillin streptomycin 
amphotericin B 1× solution (Sigma Chemical Co. Aldrich St. Louis, MO) and used between passages 4 to 10 
to avoid cellular senescence. Transfection was performed using Lipofectamine (Life Technologies, Carlsbad, 
USA) following manufactures’ protocols. When co-transfection was performed, MVK and GFP-RhoA or GFP-
RhoAF plasmids were used in a 10:1 ratio, to minimize the chance to have cells with only one plasmid. To 
assess impairment of autophagic flux, cells were treated with Bafilomycin A1 (Sigma Chemical Co. Aldrich 
St. Louis, MO) 5 nM for 16h then processed for western blot.
Fig. 1. Mevalonate kinase pathway and transient expression model of MKD. (a) Schematic representation of the 
mevalonate pathway. In vitro MKD transient expression model, was established using MVK coding plasmid carry-
ing two different mutations: I268T (orange), and N301T (red) and WT (Wild-Type of MVK, yellow). The principal 
product of mevalonate pathway is cholesterol, but this metabolic pathway is also important for the production 
of farnesyl-PP and geranylgeranyl-PP that generates respectively farnesylation and geranylgeranylation of small 
GTPase, among other proteins. (b) Levels of MK protein with western blot in SH-SY5Y cells carrying WT MVK 
or mutant alleles (I268T and N301T). MK has been detected with policlonal antibody: it is possible to distinguish 
between exogenous (#) and endogenous (*) MK based on molecular weight, being the exogenous MK fused with 
MYC peptide (already present in the original plasmid used for transfection) and consequently heavier (43.5 KDa) 
than the endogenousone (42 KDa) Hsp90 is the reference protein. 
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Plasmids and site directed mutagenesis
pCMV-6 MVK-expressing plasmid (Wild Type; RefSeq: NM_000431.1) (WT) was obtained from Origene 
(Rockville, USA) (RC201971). On this template, two mutations in the coding sequence were obtained: I268T 
and N301T, using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, California). Primers 
were designed using the “PrimerX” web application (http://www.bioinformatics.org/primerx/index.htm). 
Mutagenesis was confirmed by direct sequencing. G. Del Sal (LNCIB, Trieste, Italy) kindly provided plasmids 
GFP-RhoA and GFP-RhoAF, generated from pLPC.
GFP intracellular distribution
Intracellular distribution of GFP-RhoA and GFP-RhoAF was evaluated using Nikon C2+ confocal 
microscope. Briefly, cells were grown on glass coverslip, transfected with the different plasmids and then 
stained with Vybrant® DiD cell-labeling solution (ThermoFisher) following manufacturer’s indications. 
After 20 minutes incubation cells were fixed in 4% paraformaldehyde and imaged using 63X objective: 
10-15 cell-images for each experiment were taken. Cells were acquired as stack of 20 images with a depth 
of field of 10 µm and each image was separated by 0.5 µm. Using the ‘Z-Stack projection’ plugin of Fiji 
Software [17] images stack were averaged to a single two-dimensional image. For GFP-RhoA and GFP-
RhoAF parallel images for nuclear staining (DAPI; Life Technologies) were obtained. Composite images 
formed by GFP, Vybrant® DiD and DAPI signals were made using Fiji software [19] and overlap between the 
GFP and DAPI signals was evaluated using JACoP plugin [20]; if overlap coefficient was >0.60, intracellular 
distribution was considered “cytoplasmic”. The reference value for overlap coefficient was obtained using 
cells transfected only with GFP-RhoA or GFP-RhoA-F plasmid without MVK, called not treated (NT): this 
mean value corresponds to the basal overlap coefficient between the two signals.
Western Blot
SH-SY5Y cells overexpressing MVK, either WT or I268T or N301T, were lysed in RIPA buffer (10mM 
Tris-HCl pH 8.0, 1 mM EDTA, 1% Triton X-100, 140 mM NaCl). Cellular lysates were quantified using Bradford 
assay (Biorad, Hercules, USA); equal amounts of protein were loaded on 4-20% Tris-Tricine gels (Biorad) 
and transferred on nitrocellulose membrane (Biorad, Hercules, USA). Membranes were then incubated with 
primary antibodies and then developed with HRP-conjugated secondary antibodies and Clarity™ substrate 
(Biorad Hercules, USA). Primary antibodies were: anti-MVK (Origene, Rockville, USA; TA313341); anti-
hsp90 (SantaCruz, Dallas, USA); anti-LC3 (Sigma Chemical Co. Aldrich St. Louis, MO), anti-p62 (SantaCruz, 
Dallas, USA).
Apoptosis analysis
Apoptosis was evaluated in SH-SY5Y cells expressing pCMV-6 plasmid with MVK mutations, using 
flow cytometry (Annexin V-FITC Apoptosis Detection Kit, Immunostep, Spain). Fluorescence was acquired 
with CyAn ADP analyser and Summit software (Beckman Coulter, Brea, CA, USA), then analysed with FlowJo 
software (version 7.6, Treestar, Inc., St Ashland, OR, USA).
Statistical Analysis
Statistical significance was calculated using one-way ANOVA with Bonferroni post hoc test correction. 
Analyses were performed using GraphPad Prism software (version 5.0, GraphPad Software, Inc., La Jolla, 
CA, USA).
Results
Mutant MK expression 
We obtained two mutated MK versions using site-directed mutagenesis on plasmid 
carrying MVK wild-type cDNA sequence. Giving the fact that MK mutated proteins could 
have different stabilities (half-life), as a first step, we assessed protein levels in SH-SY5Y cells 
carrying MVK WT or mutant alleles (I268T and N301T). As shown in Fig. 1b, SH-SY5Y cells 
showed homogeneous increase of MK protein levels independently of the genetic variants 
carried, thus demonstrating that all variants have similar stability.
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Protein prenylation levels assessment
Considering that one of the demonstrated effects of mevalonate pathway alteration, 
also caused by mutated MK, is the diminished levels of prenyl-groups, specifically farnesyl-
pyrophosphate and geranylgeranyl-pyrophosphate, necessary for secondary modifications 
of specific proteins, we determined the effect of MVK I268T and N301T mutations on proteins 
prenylation. To this aim, we co-expressed either WT or mutant proteins together with two 
different fluorescent sensors, specifically GFP-RhoA-F to assess farnesylation, and GFP-RhoA 
to evaluate geranylgeranylation.
Although novel, this technique has been previously validated as shown in the article of 
Sorrentino and co-authors [21] and it is a widely accepted methodology to assess protein 
prenylation levels. 
As shown in Fig. 2a, GFP-RhoA-F or GFP-RhoA alone, in NT condition, localized in cellular 
membranes, most prominently in perinuclear region, this localization is also confirmed by 
co-localization with Vybrant DiD plasma membrane staining and GFP. Instead, in transfected 
cells with MVK, GFP-RhoA-F or GFP-RhoA the localization is considered cytoplasmic; in fact, 
it is diffused into cytosol and not only in cellular membranes; moreover plasma membranes 
are mainly marked with Vybrant DiD.
In order to obtain an unbiased measure, we decided to use an objective parameter 
to quantify the number of cells possessing a cytoplasmic localization of these GFP- based 
Fig. 2. Mutations in MVK causes alterations of farnesylation and geranylgeranylation of proteins. (a) SH-SY5Y 
transiently transfected with GFP-RhoA-F or GFP-RhoA. GFP–RhoA-F with a farnesylation consensus sequence 
is sensitive to farnesylation; indeed, GFP–RhoA with a geranylageranylation consensus sequence is sensible to 
geranylgeranylation. Representative images are shown. In red, membrane staining with Vybrant® DiD. I268T 
and N301T demonstrate the cytosolic distribution. Scale bars, 10 μm. (b) Percentages of cells with cytosolic dis-
tribution of GFP-RhoA-F and with cytosolic distribution of GFP-RhoA according to MVK sequences carried are 
reported. Data are derived from n = 3 independent experiments; 10-15 cell images for each experiment were taken. 
NT = not transfected cells, WT = Wild-Type MVK, I268T=MVK mutated I268T, N301T=MVK mutated N301T. 
Statistical significance was calculated using one-way ANOVA with Bonferroni post hoc test correction. *P < 0.05; 
**P < 0.01, ***P < 0.001, ns: not significant.
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sensor: the co-localization coefficient, obtained using overlap of the blue (DAPI) signal with 
the green (GFP) signal. This coefficient (see materials and methods) was obtained using FiJi, 
software for image analysis [17, 18]. We used as a baseline the coefficient obtained using 
cells transfected only with GFP-RhoA or -RhoAF, hypothesising that this would represent 
the “normal” distribution of these sensors. As a positive control, we treated cells with 
Lovastatin, obtaining a mean co-localization coefficient of almost 1, representing complete 
co-localization (data not shown). After setting up the conditions, we quantified the number 
of cells with a cytoplasmic localization for each condition. After transfecting with MVK I268T 
and N301T, we observed a significant increase of the number of cells with GFP-RhoA-F and 
GFP-RhoA cytoplasmic localization (%GFP-RhoA-F cytoplasmic: I268T 44.54 ± 2.11, p < 
0.001; N301T 54.94 ± 7.92, p < 0.001) (%GFP-RhoA cytoplasmic: I268T 44.10 ± 0.07, p < 
0.001; N301T 51.19 ± 1.08, p < 0.001) when compared with NT condition (%GFP-RhoA-F and 
%GFP-RhoA cytoplasmic: NT:0) (Fig. 2b); in SH-SY5Y carrying N301T mutation, we detected 
a significantly increase of cells with GFP-RhoA-F and GFP-RhoA cytoplasmic localization if 
compared with WT (%GFP-RhoA-F cytoplasmic: WT 32.79 ± 9.39, p < 0.01) (%GFP-RhoA 
cytoplasmic: WT 25.75 ± 5.87, p < 0.001); instead in SH-SY5Y with I268T mutation the 
increase becomes significant only for the GFP-RhoA localization when compared to WT (Fig. 
2b).
Autophagic flux disarrangement 
Autophagy is a well-coordinated process that contributes to the removal of unused or 
damaged proteins and organelles [22, 23]; autophagy is regulated by a variety of proteins, 
and numerous GTPases intervene in this mechanism. One of the activation mechanisms 
of GTPase is prenylation, necessary to move these proteins into membranes, where they 
Fig. 3. MVK mutations induce defective autophagy. (a) Representative Western blots showing expression of LC3-
II, LC3-I, p62 and HSP90, the latter used as the reference protein. NT= not transfected cells, WT=Wild-Type MVK, 
I268T=MVK mutated I268T, N301T=MVK mutated N301T, Baf = Bafilomycin A1 treatment. (b) Quantification 
of LC3-II increase, using LC3-II/LC3-I optical density ratio, ***P < 0.001 vs NT, one-way ANOVA with Bonfer-
roni post hoc test correction. (c) Quantification of p62 increase, normalized to HSP90 optical density. Statistical 
significance was calculated using one-way ANOVA with Bonferroni post hoc test correction. *P < 0.05;, ns: not 
significant.
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exert their functions. After observing that MVK I268T and N301T alter prenylation levels, 
we decided to investigate if the presence of MK mutants could also modify the autophagic 
process in SH-SY5Y.
As a marker of the autophagy initiation, we analysed the ratio between the lipidated 
(active) form of LC3 (LC3-II) and the non-lipidated moiety (LC3-I). As shown in Fig. 3a, the 
presence of mutated MK significantly increases LC3 lipidation (LC3II/LC3I normalized: WT 
0.305 ± 0.044, p < 0.001; I268T 0.319 ± 0.056, p < 0.001; N301T 0.341 ± 0.057, p < 0.001) 
if compared to NT (LC3II/LC3I normalized: NT 0.037 ± 0.017), thus activating autophagic 
process. Treatment with Bafilomycin A1, an inhibitor of vacuolar H+-ATPase, responsible for 
fusion between autophagosomes and lysosomes, further increases the ratio LC3-II/LC3-I 
(LC3II/LC3I normalized: Baf 1.59 ± 0.282; WT+Baf 1.94 ± 0.371; I268T+Baf 1.349 ± 0.119; 
N301T+Baf 1.303 ± 0.209), (Fig. 3b) demonstrating that the first part of autophagic process 
is still functioning. 
Sequestosome-1/p62 is a key protein further downstream of autophagic process 
interacting with LC3-II and other proteins to target them for degradation and it is itself 
degraded by autophagy; its levels are useful to monitor autophagy.
We observed that p62 levels increased in SH-SY5Y cells with expression of MVK 
WT and I268T and significantly augmented in N301T mutants (p62 normalized: WT 
0.656±0.308, ns; I268T 0.52 ± 0.093, ns; N301T 0.916 ± 0.027, p<0.05) if compared with 
NT (p62 normalized: NT 0.344 ± 0.074) (Fig. 3a and Fig. 3c). Simultaneous treatment with 
Bafilomycin A1 further augmented p62 expression (p62 normalized: Baf 1.497 ± 0.216; WT 
+ Baf 2.778 ± 0.444; I268T + Baf 2.832 ± 0.097; N301T + Baf 3.527 ± 0.141). So it is possible 
to speculate that MK mutants impair autophagic process, further downstream of the fusion 
between autophagosomes and lysosomes, because p62 not degraded and co-treatment with 
Bafilomycin A1 further increases the expression of this protein.
Fig. 4. MVK mutations cause apoptosis in SH-SY5Y. (a) Representative flow cytometry plots of SH-SY5Y cells car-
rying WT MVK or mutant proteins (I268T and N301T) stained with Annexin V and Propidium Iodide. Dot plots 
show the staining with Annexin V FITC and Propidium Iodide after gating on FSC/SSC to exclude debris. Numbers 
in the corners of quadrants represent the percentage of the total. (b) Quantification of apoptotic cells, showing the 
average of % Annexin positive cells (%A+) ± standard deviation (S.D.) of three independent experiments. NT= 
not transfected cells, WT=Wild-Type MVK, I268T=MVK mutated I268T, N301T=MVK mutated N301T. Statistical 
significance was calculated one-way ANOVA with Bonferroni post hoc test correction. *P < 0.05; **P < 0.01, ns: 
not significant.
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Apoptosis
Autophagy impairment is responsible for activation of apoptotic cell death in different 
disease models, specifically of neurodegenerative diseases [24–26]. It was then investigated 
if apoptotic cell death is modulated in SH-SY5Y transfected with MVK WT or I268T or N301T 
mutations.
Overexpression of MK mutants provoked an increase of apoptotic cell death; these 
results are also graphically evident in flow cytometric plots (Fig. 4a): the effect of transfection 
with MVK (WT, I268T or N301T mutations) on apoptosis can be clearly observed in the 
upper and lower right quadrants (Q2 and Q3 respectively) of dot plot compared with the 
same quadrants of dot plot in NT condition. Of note, the overproduction of MK protein in WT 
caused augmented apoptosis (%A+: WT 29.06 ± 4.11, p < 0.05) with respect to NT conditions 
(%A+: NT 17.76 ± 6.01); we also observed a significant increase of apoptosis in the presence 
of I268T and further increase in N301T (%A+: I268T 31.17 ± 2.95, p < 0.05; N301T 33.57 ± 
1.40, p < 0.01) (Fig. 4b).
Discussion
Mevalonic Aciduria (MA), a severe form of MKD characterized by neurologic impairment, 
is caused by mutations at MVK gene that encodes for MK enzyme. The genotype/phenotype 
Fig. 5. Mutation hot spot regions in mevalonate kinase enzyme and MKD pathogenic pathway observed. (a) the 
hot spot regions (comprised between residues 8-35 and 234-338, highlighted in yellow) in mevalonate kinase 
(MK) enzyme sequence are schematically represented. The two mutations involved in the study are depicted in the 
sequence of MK: I268T (orange), and N301T (red). (b) autophagic flux is represented: LC3-I (non-lipidated) is con-
verted into lipidated (active) form of LC3 (LC3-II); LC3-II mediates membrane elongation by associating with au-
tophagosomal membrane. Adaptor protein p62 directly binds to ubiquitinated (Ub) proteins and acts as a receptor 
for Ub proteins. Subsequently, the autophagosome fuses with the lysosome to form an autophagolysosome. Finally 
all the proteins are degraded in the autophagolysosome and recycled. In red boxes the possible MKD pathogenic 
pathway is depicted: MVK mutations (I268T and N301T) result in decrease in farnesylation and geranylgeranyla-
tion levels. Decrease of prenylated proteins induces autophagy impairment causing apoptotic cell death.
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correlation is not completely known and the entire pathogenic mechanism at the basis of the 
disease is only hypothetical, strongly needing to be experimentally unravelled. This lack of 
experimental evidence for genotype/phenotype correlation is mainly due to the absence of 
viable and reproducible models (either animal or cellular) useful to mimic the impact of MVK 
mutations on the etiopathogenesis of MKD.
MVK-null cells are not viable: either MVK-KO or double dose MVK mutation in 
homozygosis or compound heterozygosis is not compatible with cell life. Silencing 
technology has been also used in the attempt to obtain MVK-null cells [27] but no positive 
results have been achieved, having been able only to partially silencing MVK (around 40% of 
efficiency). Several researchers tried to obtain a MVK KO mouse strain to mimic the effects of 
the mutations in animal model, but MVK-/- mice are not viable (they die in early embryonic 
stages) [28, 29]. We also tried to introduce the mutations such as I268T and N301T, using 
CRISPR/Cas9 system, but it has been impossible to obtain viable MVK null/null cells. At 
present, the Lovastatin driven biochemical block of mevalonate pathway has given the most 
exhaustive findings on the impairment of this pathway in cell models [15, 17]. 
All this considered, we tried to unravel the effect of selected MVK mutation (I268T, 
associated to mild and severe MKD, and N301T specifically associated to MA) using a 
transient expression model in neuronal cell line (SH-SY5Y). 
Our results suggest that mevalonate pathway impairment, due to these two MVK 
mutations, causes decreased levels of farnesylation and geranylgeranylation, which 
theoretically may trigger the impairment of autophagy. In our neuronal cell model, N301T 
mutation associated to MA, leads to a decrease in prenylated protein level, compared to 
I268T mutation associated to mild/severe MKD. This could prime an additional impaired 
autophagy, deduced by increased LC3 lipidation and increase of p62 levels in the presence of 
N301T mutation in comparison to I268T mutation; this apparent block of autophagy could 
be indeed cause of increased apoptosis (greater in the presence of N301T mutation when 
compared to I268T). We can hypothesize that the incremented apoptosis observed in the 
presence of N301T mutation could be involved, at least in part, with the severe neuronal 
phenotype observed in MA patients [30]. 
When considering the impact of I268T and N301T MVK mutations we observed that 
N301T, associated with MA, showed a more severe response for all observed variables if 
compared to I268T mutation associated to severe/mild MKD (Fig. 5a). Both mutations occur 
in the in silico predicted hotspot regions for MA (Fig. 5b and Fig. 1a in Browne et al. [12]), 
and they both localizes in α-helices at the dimer interface of MK enzyme [12]. It is possible 
to speculate that the two mutations alter in different manner the enzyme dimerization; 
however, there are no molecular dynamics data elaborating the effect of MVK mutations on 
the ability of MK to dimerise. 
The crosstalk between autophagy and apoptosis pathways has been demonstrated in 
different models [31]. Recently, in traumatic brain injury model, it was found that markers 
of increased and blocked autophagic flux co-localize with activated caspase-3. These results 
suggest that autophagy blockade could lead to apoptosis [32]. 
Autophagy is a complex process, multiple pathways are known to regulate and control 
this specific mechanism also with the intervention of numerous small GTPases, (for a 
complete review, see [33]) necessitating prenylation to correctly function. Although using a 
transient knock-in MVK genetic model, our study suggests a tight link between impairment 
in autophagic flux and mevalonate pathway dysfunction, followed by cell death [34]. A recent 
work in patients with rheumatoid arthritis demonstrated that increasing autophagic flux 
could be beneficial toward lowering markers of inflammation [35] and a previous study 
also demonstrated that everolimus (inhibitor of mTor pathway) treatment, concomitant 
with methotrexate, could improve symptoms of patients suffering of rheumatoid arthritis 
[36]. Van der Burgh and co-authors have previously shown that treatment of MKD patients’ 
monocyte with rampamycin, inhibitor of mTor pathway, slightly diminish IL-1β secretion 
after LPS challenge, although not to levels similar to the control [37]. These data showed 
how autophagy is a complex process and other possibly involved molecules need to be 
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evaluated. Furthermore, our findings support the key role of autophagy in MKD suggesting 
that mevalonate pathway disturbances could be responsible for autophagic flux blockade. 
A recent study indicates that the Rab family of GTPase is not involved into release of 
IL-1β from MKD patients monocytes after an high temperature stimulus [38]. Rab GTPases 
necessitate of geranylgeranyl post-translational modification to be attached to membranes 
and then activated; thus these results further confirm our findings on the important role of 
farnesylation and not only geranylgeranylation in MKD pathogenesis. So, both prenylation 
pathways could be simultaneously involved, causing the decrease of active GTPases.
Moreover, Veluthakal and co-authors demonstrated that metabolic disturbances, 
specifically ER stress and mevalonate pathway blockade might cause accumulation of 
unprenylated trimeric-G-proteins. This appears to be due to the caspase-3 activation 
that degrades farnesyl and geranylgeranyl transferase cleaving a-subunit of farnesyl and 
geranylgeranyl transferase [39]. This work demonstrates how metabolic stress could affect 
prenylation pathway, generating a wide cellular response.
We are aware that our study, having been performed using a MVK mutated transient 
genetic model has various limitations, being over-expression of the target protein the most 
important one. This could lead to damages independently of the mutations, being MK WT, 
I268T and N301T all overexpressed on the same level and all causing increase on programmed 
cell death. In fact, it is thus possible that cholesterol pathway is altered simply by the enzyme 
increased levels, thus leading to apoptosis; however, our results using prenylation-sensitive 
GFP demonstrate that MVK mutants have a different effect, significantly reducing the levels 
of prenylated proteins (see Fig. 2b). So, the relative small differences observed in apoptotic 
cell death between WT and mutant MVK (see Fig. 4b) could be due to a confounding effect 
in which overexpression of MVK “masks” the effect of mutants by increasing the tendency 
to apoptosis. All this considered we have to cautiously consider the effects of MVK transient 
mutations on apoptosis.
Taken together our results indicate a possible correlation between mevalonate pathway 
alteration, decrease of prenylated proteins levels, defective autophagy and apoptosis (Fig. 5).
To date, MKD is still an “orphan” disease, treatment is only supportive and there is 
no evidence-based therapeutic protocol. It will then be crucial to understand MKD and 
MA pathogenic mechanism in order to identify novel proteins involved, to the final aim of 
identifying effective therapeutic targets. 
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